Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF 322.30
+1.60 (0.50%)
Inactive · Last trade price on Mar 16, 2026
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B
Revenue Growth
+1.54%
P/S Ratio
4.06
Revenue / Employee
613.62K
Employees
103,249
Market Cap
257.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | 59.50B | 3.75B | 6.73% |
| Dec 31, 2017 | 55.75B | 3.11B | 5.91% |
| Dec 31, 2016 | 52.64B | 2.23B | 4.43% |
| Dec 31, 2015 | 50.40B | 537.00M | 1.08% |
| Dec 31, 2014 | 49.87B | 1.25B | 2.58% |
| Dec 31, 2013 | 48.61B | 1.17B | 2.46% |
| Dec 31, 2012 | 47.44B | 3.33B | 7.55% |
| Dec 31, 2011 | 44.11B | -5.05B | -10.28% |
| Dec 31, 2010 | 49.17B | -1.98B | -3.88% |
| Dec 31, 2009 | 51.15B | 3.25B | 6.78% |
| Dec 31, 2008 | 47.90B | -472.00M | -0.98% |
| Dec 31, 2007 | 48.38B | 4.94B | 11.38% |
| Dec 31, 2006 | 43.43B | 6.47B | 17.52% |
| Dec 31, 2005 | 36.96B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRoche Holding AG News
- 3 days ago - Louth GAA FL Round-up - Div 2: O’Raghallaighs pick up vital points as Roche open six-point lead at the top - Independent Ireland
- 3 days ago - Exelixis Announces STELLAR-303 Trial Results For Zanzalintinib Combination - Nasdaq
- 6 days ago - The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs - WSJ
- 6 days ago - U.S. opens tariff probe targeting Germany's drug pricing policies - CNBC
- 7 days ago - Roche (RHHBF) Receives FDA Acceptance for Lunsumio VELO Label Expansion - GuruFocus
- 7 days ago - FDA Accepts Genentech's SBLA For Lunsumio-Polivy In LBCL; Decision Slated For February 2027 - Nasdaq
- 7 days ago - FDA accepts supplemental Biologics License Application for Roche's Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma - GlobeNewsWire
- 7 days ago - FDA Accepts Supplemental Biologics License Application for Genentech's Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma - Business Wire